Asian, indigenous, Latino patients underrepresented in US clinical trials of biologics

Asian, indigenous, Latino patients underrepresented in US clinical trials of biologics

Asian, American Indian, Alaska Native, Latino and Hispanic patients are underrepresented in U.S. clinical trials for new drugs and biologics, compared with national census figures, according to a research letter published in JAMA.Meanwhile, trial participation rates among Black and white patients were generally consistent with, or above, U.S. Census figures from 2015 to 2019, the researchers wrote.“Concerns have been raised over racial and ethnic representation in clinical trials,” Milena Lolic, MD, MS, of the FDA Office of the Commissioner, in Silver Spring, Maryland, andRead More

Share on facebook
Share on twitter
Share on linkedin